Core Insights - The company is focused on patient care, emphasizing positive outcomes in quality and safety for the year-to-date [2] - Employee engagement and satisfaction are improving, with a workforce of 315,000 serving 44 million patients last year [3] Company Performance - The company has reported positive trends in patient care outcomes, indicating effective efforts from clinical teams [2] - Retention and turnover reduction are prioritized, alongside workforce development initiatives like the Galen School of Nursing and physician residency programs [3]

Core Insights - DaVita faced notable challenges in 2025, including a tough flu season in Q1 and a significant cyber incident in Q2 [2] - Despite these challenges, DaVita managed to maintain its guidance and continue delivering operating results [3] Group 1: Challenges Faced - The primary challenges for DaVita were related to volume, which is a key metric for the company and investors [3] - Revenue per treatment also posed challenges during the year [3] Group 2: Company Performance - DaVita's management effectively handled the cyber incident, showcasing the company's operational resilience [2] - The company is focused on navigating through the challenges while ensuring operational performance remains strong [3]

Performance Overview - The Jot ETF has achieved a 69% increase since its launch five years ago [1][2] - The ETF's performance is attributed to various momentum factors and its strategic usage as a core investment [2] Market Insights - Current market conditions are characterized by volatility, leading to a cautious outlook [3] - United Healthcare is highlighted as a safer investment option amidst market uncertainty [3] - There is an expectation of government-level resolutions in the healthcare sector, which could act as a catalyst for market movements [4] Notable Stocks - Monster Beverage is mentioned as a significant player within the consumer staples sector [4]

Market Performance - Major U.S. indexes showed mixed performance last week, with the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average declining by 2.7%, 1.4%, and 0.5% respectively [1] - Investors are shifting focus from high-valuation technology and AI stocks to more defensive sectors due to market volatility [1] Federal Reserve and Economic Data - The end of a 43-day government standoff has reduced political risks, but delays in key economic data releases have created uncertainty for the Federal Reserve and investors [2] - The Fed is balancing economic growth and inflation, with inflation remaining above the 2% target and a resilient labor market casting doubt on December rate cut expectations [2] Zacks Research Performance - Zacks Research has provided guidance that led to significant stock performance, with Macy's shares increasing by 14.9% since its upgrade to Zacks Rank 1 on September 18, outperforming the S&P 500's 2.2% increase [3][4] - Fresnillo plc also saw a 7.2% return since its upgrade to Zacks Rank 1 on September 19, compared to the S&P 500's 1.8% increase [4] Zacks Model Portfolio Returns - A hypothetical portfolio of Zacks Rank 1 stocks returned +8.64% in 2025 through September 1, outperforming the S&P 500's +7.60% [4] - The Zacks Model Portfolio has outperformed the S&P 500 index by over 12 percentage points since 1988, with an annualized average return of +23.8% compared to +11.3% for the S&P 500 [5] Specific Stock Performances - United Natural Foods, Inc. (UNFI) shares increased by 32.4% after its Zacks Recommendation was upgraded to Outperform [7] - Caterpillar Inc. (CAT) gained 35.9% over the past 12 weeks, while CACI International Inc. (CACI) returned 20.1% during the same period [10] Earnings Certain Admiral Portfolio (ECAP) - The ECAP returned -1.30% in Q3 2025, underperforming the S&P 500's +8.1% gain, and +2.72% year-to-date compared to the S&P 500's +14.84% [15] - The portfolio aims to minimize capital loss by holding shares of companies with a proven track record of earnings stability [16] Earnings Certain Dividend Portfolio (ECDP) - Johnson & Johnson (JNJ) returned 10.9% over the past 12 weeks, while UnitedHealth Group (UNH) increased by 5.9% [18] - The ECDP returned -0.01% in Q3 2025, underperforming the S&P 500's +8.1% gain [20] Top 10 Stock Portfolio - MasTec, Inc. (MTZ) has jumped 41.2% year-to-date, outperforming the S&P 500's 14.7% increase [22] - The Top 10 portfolio has produced a cumulative return of +2,553.1% since 2012, significantly outperforming the S&P 500's +545.2% [24]

Core Insights - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company increased its professional liability reserves by $54 million due to adverse developments from claims made between 2019 and 2022, as well as broader industry trends [3]. - Following the financial disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [3].

Leadership Changes - Krista Nelson has been appointed as the new CEO of Optum Health, effective immediately, replacing Dr. Patrick Conway [1][2] - Dr. Patrick Conway will continue to serve as the CEO of Optum following this leadership change [3] Executive Background - Krista Nelson has been with UnitedHealthcare and UnitedHealth's payer arm since 2009, most recently overseeing the growth of government programs before becoming COO of Optum Health in May [2] - The company has seen rapid executive changes, including the recent departure of CFO Roger Connor and the appointment of Ben Eklo as his replacement [4] Performance Issues - Optum Health underperformed investor expectations in the third quarter, facing challenges related to rapid provider network expansion and reimbursement cuts from the Biden administration [5] - The new leadership is expected to implement changes such as transitioning to a direct physician employment model and cutting unprofitable members to improve performance [5]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. - Following the financial disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages investors to seek additional information regarding their legal options [2][5]. - The law firm has a strong track record in securities class actions, having recovered significant amounts for shareholders in previous cases [6].

Core Insights - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company increased its professional liability reserves by $54 million due to adverse developments from claims between 2019 and 2022, as well as broader industry trends [3]. - Following the financial disclosures, Ardent's stock price dropped over 33% on November 13, 2025 [3]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages affected investors to seek additional information regarding potential legal options [1][4].

Core Insights - Kirby McInerney LLP is investigating potential claims against Ardent Health, Inc. regarding possible violations of federal securities laws or unlawful business practices [1][3] Financial Results - On November 12, 2025, Ardent announced its third-quarter financial results, revealing a $43 million reduction in revenue due to changes in accounting estimates related to accounts receivable [3] - The company also disclosed a $54 million increase in professional liability reserves for claims in New Mexico [3] - Following this announcement, Ardent's share price fell by $4.75, approximately 33.8%, from $14.05 to $9.30 [3]

Core Insights - Hims & Hers Health, Inc. has launched Labs, a new service aimed at helping customers understand and improve their overall health [1][2] - The company anticipates that this offering could evolve into a $1 billion business, targeting a broad market [5] Product Offering - Labs measures key health markers over time and provides doctor-developed action plans, focusing on areas such as heart health, metabolism, hormones, inflammation, and stress [2][6] - Two plans are available: - Base plan includes one yearly blood draw with 50 biomarker tests for $199 - Advanced plan includes two yearly blood draws with over 120 biomarker tests for $499 [4][7] Market Access and Strategy - Customers will access testing at over 1,000 Quest Diagnostics locations nationwide, receiving results and personalized plans through the Hims & Hers platform [6] - The company plans to expand its offerings to include at-home testing devices and additional biomarker tests in areas like bone and brain health [3] Financial Performance - For the third quarter, Hims & Hers reported revenue of $598.97 million, surpassing the estimate of $580.24 million, with a 21% year-over-year increase in subscribers to nearly 2.5 million [8] - The company projects fourth-quarter revenue between $605 million and $625 million, slightly below the analyst estimate of $631.68 million [8]